Magellan leveraging industry-leading therapeutic apps in new markets
via FDA clearance to help people with insomnia, substance abuse,
depression and anxiety
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--
Magellan
Health (NASDAQ: MGLN), recognized as a leading provider of
software-based tools to increase the integration of and access to
behavioral health treatment, continues to develop digital therapies by
expanding its collaboration with Click Therapeutics to pursue a new
avenue: Food and Drug Administration (FDA) clearance for therapeutic
apps. Click will leverage Magellan's portfolio of software programs and
associated intellectual property and data to create mobile apps for
people challenged by conditions such as insomnia, substance abuse,
depression and anxiety and apply for FDA clearance for such apps on the
basis of valid scientific evidence supporting the safety and
effectiveness of the software. This augments Magellan's work to provide
broad-based, digital and data-driven programs for primary care and
specialty care providers.
"This collaboration is a great example of how Magellan is utilizing its
industry-leading capabilities to provide healthcare solutions to people
in a convenient and personalized way," said Barry M. Smith, chairman and
chief executive officer of Magellan Health. "Click has a similar
interest in the market, and both companies have complementary skill
sets. I'm excited to continue our work together."
"Using the industry-leading suite of intellectual property and data from
Magellan's existing software, integrated with Click's leading patient
engagement platform, Click will seek regulatory clearance from the FDA
to provide indication-specific prescription digital therapies," said
David Benshoof Klein, chief executive officer of Click Therapeutics. "We
appreciate Magellan's innovative spirit and focus on helping people
address common mental health challenges in a personalized and convenient
way, and are excited to leverage Magellan's vast coverage and
reimbursement expertise to make digital therapeutics widely accessible
to commercial and government health insurance beneficiaries."
Last year, Magellan launched a tobacco cessation program with Click
Therapeutics leveraging Magellan's clinical coaching and pharmacy
benefit management (PBM) capabilities with Click's technology and
machine learning platform, including the mobile application, CLICKOTINE®,
to create an all-in-one solution.
Magellan's computerized cognitive behavioral therapy (CCBT) modules have
undergone numerous clinical trials in which they have matched, and in
some instances exceeded, those reached by conventionally delivered
cognitive behavioral therapy. In addition, Cobalt has received the
highest rating from the Substance Abuse and Mental Health
Administration's (SAMHSA) National Registry of Evidence-based Programs
and Practices (NREPP).
About Click Therapeutics: Click Therapeutics, Inc. engineers,
validates, and commercializes Digital Therapeutics™ solutions to benefit
people with unmet medical needs through cognitive and neurobehavioral
modification. Click Therapeutics™ digital interventions enable change
within individuals, and can be used independently or in conjunction with
biomedical treatments. The Clickometrics® adaptive data
science platform continuously personalizes user experience to drive
cognitive and behavioral outcomes. As the leader in Digital
Therapeutics™ solutions, Click Therapeutics is building the brains
behind digital health. For more information, visit ClickTherapeutics.com.
About Magellan Health: Magellan
Health, Inc. is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
supports innovative ways of accessing better health through technology,
while remaining focused on the critical personal relationships that are
necessary to achieve a healthy, vibrant life. Magellan's customers
include health plans and other managed care organizations, employers,
labor unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170815005359/en/
Magellan Health, Inc.
Media Contact:
Colleen Flanagan
Johnson, 860-507-1923
cefjohnson@magellanhealth.com
or
Investor
Contact:
Joe Bogdan, 860-507-1910
jbogdan@magellanhealth.com
Source: Magellan Health, Inc.
News Provided by Acquire Media
